Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
Overview
Pfizer (NYSE:PFE), a large-cap biopharmaceutical company focused on medicines, vaccines, and specialty therapeutics, closed at $25.21, down 2.74%. This morning's CFO transition announcement and succession review kept investors focused on 2026 guidance and leadership continuity.
The company’s trading volume reached 67.9M shares, which is roughly 85% above its three-month average of 36.6M shares.
Details
The S&P 500 (SNPINDEX:^GSPC) rose 1.05% to 7,500.58, while the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.91% to 26,518. Among global biopharmaceuticals; research, development, manufacturing, and commercialization of prescription medicines and vaccines, Merck (NYSE:MRK) fell 1.36% to $113.87, and Bristol-Myers Squibb (NYSE:BMY) dropped 2.32% to $54.00.
Source
Originally published at www.fool.com.
